Overview
Conference: October 28-30, 2024 | In-Person
Co-sponsored with FDA!
The DIA/FDA Oligonucleotide-Based Therapeutics Conference brings together leading experts to inform, educate, and share advancements in oligonucleotide-based therapeutic product development. Developed collaboratively by regulators, industry professionals, and academics, the program covers a wide range of topics from the nonclinical, CMC, and clinical areas. The conference offers a unique experience with multiple perspectives presented, and the opportunity to interface with regulators from around the globe.
While we develop our 2024 agenda, please take a moment to review the 2022 final agenda
Participant Testimonials
Event was well organized and of very good quality. Especially, the participation from members of regulatory authorities (FDA, EMA, BfARM) was extremely helpful and interesting. – Sabrina Eisheuer, BioSpring GmbH
Speakers are well selected in this conference. A great opportunity to talk to people knowledgeable in this field.! – Zheng Li, FDA
Featured
Want to learn more about DIA/FDA Oligonucleotide-Based Therapeutics Conference? You've come to the right site!
Program Committee
-
Scott Henry, PhD Vice President, Nonclinical Development
Ionis Pharmaceuticals, Inc., United States -
Ronald Wange, PhD Associate Director for Pharm/Tox, OND, CDER
FDA, United States -
Barry Ticho, MD, PhD Chief Medical Officer
Stoke Therapeutics, United States -
Benjamin Stevens, PhD, MPH Director CMC Policy and Advocacy
GlaxoSmithKline, United States -
Louis O'Dea, MD Chief Medical Officer and President
BIORCHESTRA (USA) Inc, United States -
Hobart Rogers, PharmD, PhD Pharmacologist
FDA, United States -
Andrew Slugg, MBA, MS Senior Vice President, Global Head of Regulatory Affairs
Alnylam Pharmaceuticals, United States -
Amy Kao Medical Officer, Division of Neurology 2, OND, CDER
FDA, United States -
Dan Swerdlow, MD, PhD Senior Director, Early Clinical Development
GSK, United Kingdom -
Patrik Andersson, PhD Senior Director, RNA Therapeutics Safety
AstraZeneca R&D, Sweden -
Elena Braithwaite, PhD Toxicologist
FDA, United States -
David Cantu Biological Reviewer, CBER
FDA, United States -
Xuan Chi, MD, PhD Supervisory Pharmacologist
CDER, FDA, United States -
Jeffrey Foy, PhD Vice President, Toxicology
PepGen Inc., United States -
Arthur A. Levin, PhD CSO
Avidity Biosciences , United States -
Daniel Capaldi, PhD Vice President, Analytical and Process Development
Ionis Pharmaceuticals, Inc, United States -
Ramin Darvari, PhD, MS Associate Research Fellow
Pfizer Inc., United States -
Brian Doyle Director, LNP Process Development
Moderna, United States -
Ramesh Raghavachari, PhD Chief, Branch I, DPMA1, OLDP, OPQ, CDER
FDA, United States -
René Thürmer, PhD Deputy Head of the Unit Pharmaceutical Biotechnology BfArM
Federal Institute for Drugs and Medical Devices, Germany -
Fran Wincott, PhD President
United States -
Christian Wetter, PhD Technical Regulatory Advisor
Roche, Switzerland -
Representative Invited DIA, United States
-
Paul C. Brown, PhD Associate Director for Pharmacology and Toxicology, OND, CDER
FDA, United States -
James Wild, PhD Pharmacologist, CDER
FDA, United States
Have an account?